ArticleFrontiers in immunology2025

Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study.

Chengzhi Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.